73
Participants
Start Date
December 21, 2020
Primary Completion Date
February 4, 2022
Study Completion Date
July 22, 2022
TALZENNA capsule
Current commercial talazoparib formulation 1 mg once daily given under fasting condition
Talazoparib soft gel capsule
Proposed talazoparib soft gel capsule formulation 1 mg once daily under fasting condition
Talazoparib soft gel capsule
Proposed talazoparib soft gel capsule formulation 1 mg once daily under fed condition
Liverpool Cancer Therapy Centre, Liverpool
Liverpool Hospital, Liverpool
Epworth Healthcare (Epworth Freemasons Hospital), East Melbourne
Epworth Healthcare, East Melbourne
Epworth Healthcare, East Melbourne
Epworth Healthcare, Richmond
Epworth Richmond Hospital (Epworth Healthcare), Richmond
Monash Health, Clayton
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
NYU Investigational Pharmacy, New York
NYU Langone Medical Center (Tisch Hospital), New York
Montefiore Medical Center, The Bronx
NYU Langone Hospital - Long Island Oncology, Mineola
NYU Langone Hospital - Long Island, Mineola
UPCI Investigational Drug Service, Pittsburgh
UPMC Hillman Cancer Center, Pittsburgh
Upmc Shadyside, Pittsburgh
Florida Cancer Specialists, Lake Mary
University Hospitals Cleveland Medical Center, Cleveland
West Chester Hospital, West Chester
University of Cincinnati Medical Center, Cincinnati
Alliance for Multispecialty Research, LLC, Kansas City
Mary Crowley Cancer Research - Medical City Hospital, Dallas
NEXT Oncology, San Antonio
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Cedars-Sinai Medical Center, Los Angeles
California Cancer Associates for Research and Excellence, Inc (cCARE), Encinitas
California Cancer Associates for Research and Excellence, Inc (cCARE), San Marcos
Smilow Cancer Hospital at Yale New Haven, New Haven
Yale-New Haven Hospital, New Haven
Smilow Cancer Hospital Phase 1 Unit, New Haven
Lead Sponsor
Pfizer
INDUSTRY